Literature DB >> 21976399

Progressive multifocal leukoencephalopathy associated with mycophenolate mofetil treatment in a woman with lupus and CD4+ T-lymphocyte deficiency.

A M Pavlovic1, B Bonaci-Nikolic, D Kozic, J Ostojic, M Abinun, T Svabic-Medjedovic, M Nikolic, N Sternic.   

Abstract

There is an increase in the number of patients with systemic lupus erythematosus (SLE) reported as developing progressive multifocal leukoencephalopathy (PML) while on intensive immunosuppressive therapy. A 39-year-old HIV-negative woman with a 10-year history of SLE presented with progressive left-side weakness while on maintenance therapy with oral prednisone and mycophenolate mofetil (MMF). On several occasions low CD4+ T-lymphocyte counts were found (68/µL). Brain magnetic resonance imaging (MRI) revealed a large lesion in the right subcortical fronto-parietal region and a smaller one in the left frontal subcortex, corresponding to the PML. In cerebrospinal fluid, polymerase chain reaction (PCR) for JC virus (JCV) was negative, but anti-JCV antibodies were highly positive. Diagnosis of probable PML was made and MMF was withdrawn. The patient's condition improved with marked reduction of left-side weakness and an increase in CD4(+) T-lymphocyte count (141/µL). Follow-up MRI showed regression of lesions and over the next 6 months the patient remained stable. In spite of the grave prognosis associated with PML, SLE patients can have an excellent outcome if immunosuppressants are discontinued as soon as the correct diagnosis is made. SLE patients with associated low CD4(+) T-lymphocyte counts should be monitored for the development of PML during immunosuppressive therapy in particular.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21976399     DOI: 10.1177/0961203311416693

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  7 in total

Review 1.  Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.

Authors:  Eleni I Kampylafka; Harry Alexopoulos; Marinos C Dalakas; Athanasios G Tzioufas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  A prominent lactate peak as a potential key magnetic resonance spectroscopy (MRS) feature of progressive multifocal leukoencephalopathy (PML): Spectrum pattern observed in three patients.

Authors:  Duško Kozić; Mladen Bjelan; Jasmina Boban; Jelena Ostojić; Vesna Turkulov; Aleksandar Todorović; Slobodanka Lemajić-Komazec; Snežana Brkić
Journal:  Bosn J Basic Med Sci       Date:  2017-11-20       Impact factor: 3.363

Review 3.  Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals.

Authors:  Deanna Saylor; Arun Venkatesan
Journal:  Curr Infect Dis Rep       Date:  2016-11       Impact factor: 3.725

4.  Systemic lupus erythematosus, progressive multifocal leukoencephalopathy, and T-CD4+ lymphopenia.

Authors:  Mariana Brandão; Joana Damásio; António Marinho; Ana Martins da Silva; Júlia Vasconcelos; Esmeralda Neves; Isabel Almeida; Fátima Farinha; Carlos Vasconcelos
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 10.817

Review 5.  Neurological Complications in Patients with Systemic Lupus Erythematosus.

Authors:  Amir Shaban; Enrique C Leira
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 6.030

6.  Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.

Authors:  Roderick P P W M Maas; Annemarie H G Muller-Hansma; Rianne A J Esselink; Jean-Luc Murk; Clemens Warnke; Joep Killestein; Mike P Wattjes
Journal:  J Neurol       Date:  2016-07-11       Impact factor: 4.849

7.  Treatment of paraneoplastic cerebellar degeneration.

Authors:  John E Greenlee
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.